Navigation Links
Surveyed U.S. and European Neurologists Agree that a Therapy's Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Date:3/20/2013

BURLINGTON, Mass., March 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that a therapy's effect on physical disability is the most influential attribute when making prescribing decisions for secondary-progressive multiple sclerosis (SP-MS)*. These same neurologists cite a therapy's effect on quality of life as the second-most important attribute, ahead of an effect on relapses, imaging metrics and other functional domains.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Current management of SP-MS relies on the use of mainline disease-modifying therapies (which include interferon-betas and Teva's Copaxone), most of which are approved broadly for the treatment of relapsing forms of MS. This category encompasses relapsing-remitting MS (RR-MS) and SP-MS patients who continue to experience relapses. Interviewed thought leaders suggest that, based on data in RR-MS, Genzyme/Sanofi/Bayer HealthCare's Lemtrada may offer advantages over sales-leading Copaxone on measures of physical disability—potentially translating into clinical benefits for SP-MS patients. 

"The neurologists we surveyed indicate that an improved effect on physical disability is one of the greatest unmet needs in SP-MS," said Decision Resources Analyst Georgiana L. Kuhlmann , S.M. "Drawing on clinical data from RR-MS trials, interviewed thought leaders indicate that Lemtrada has demonstrated the potential to partially fulfill this unmet need."

According to the DecisionBase 2013 report entitled On What Attributes Will Neurologists and Payers Differentiate Novel Therapies for Secondary-Progressive Multiple Sclerosis?, surveyed managed care organization (MCO) pharmacy directors are receptive to new SP-MS therapies that offer improvements over current therapies on disability progression, as measured by the Expanded Disability Status Scale. Nine out of ten MCO pharmacy directors report a moderate to high willingness to grant preferred formulary status to a new SP-MS therapy offering improvements on disability progression; payers appear less inclined to grant similar status to products with improvements in other areas, particularly delivery.

"In our survey, 65 percent of MCO pharmacy directors are willing to reimburse a hypothetical therapy for the treatment of SP-MS that offers once daily oral delivery," Ms. Kuhlmann said. "However, additional study data suggest that improvements in delivery burden may be less likely than other achievements to translate into preferred formulary status."

*SP-MS and primary-progressive MS (PP-MS) comprise the chronic-progressive MS (CP-MS) population.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
4. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
5. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
6. Mylan Launches Generic Lipitor® in Five European Countries
7. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
8. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
11. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
Breaking Medicine News(10 mins):